Two new classes of drugs that offer significant clinical benefits for patients with diabetes and heart failure dominated medical conferences in 2019. Meanwhile, ovarian cancer guidelines were updated to add new therapies and the intersection of consumer health technology and cardiology also took over headlines. Read on for more.
Panelists discuss how pirtobrutinib demonstrated superior progression-free survival compared with standard Bruton tyrosine kinase (BTK) inhibitors in previously treated chronic lymphocytic leukemia (CLL) patients as…
HIV infections and deaths would increase dramatically should the United States cut back on funding for the President’s Emergency Plan for AIDS Relief (PEPFAR).
In part 2 of this interview, Michael A. Bernstein, MD, highlights the need for prolonged antibiotics and strong public health measures to combat tuberculosis (TB)…
New data show states with abortion bans saw increased infant deaths, with the greatest impact on Black infants and congenital anomaly-related deaths.
Jeffrey V. Matous, MD, discusses how primary barriers to the widespread use of bispecific antibody therapies in community practices can be addressed through innovative care…
Michael A. Bernstein, MD, Stamford Health, addresses common misconceptions about tuberculosis amid the outbreak in Kansas City, Kansas.
Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite…
George Jones of UpScript Health discusses telemedicine’s evolution from basic e-prescribing to real-time video consultations, expanding treatment beyond primary care.
In an interview with The American Journal of Managed Care, Michael A. Bernstein, MD, stressed the need for effective communication and proactive screening to curb…
Sergio A. Giralt, MD, discusses the key results from recent chronic graft-vs-host disease (cGVHD) research presented at ASH 2024 and how these findings will influence…
